MedPath
HSA Approval

Suboxone 8 mg/2 mg sublingual tablets

SIN13405P

Suboxone 8 mg/2 mg sublingual tablets

Suboxone 8 mg/2 mg sublingual tablets

January 28, 2008

ZUELLIG PHARMA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZUELLIG PHARMA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, ORALLY DISINTEGRATING

SUBLINGUAL

Medical Information

N02AE01

buprenorphine

Manufacturer Information

ZUELLIG PHARMA PTE. LTD.

RECKITT BENCKISER HEALTHCARE (UK) LTD

Active Ingredients

BUPRENORPHINE HCL

8.64MG

Buprenorphine

NALOXONE HCL

2.44MG

Naloxone

Documents

Package Inserts

Suboxone Tablet PI.pdf

Approved: October 27, 2016

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Suboxone 8 mg/2 mg sublingual tablets - HSA Approval | MedPath